Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 May 27. doi: 10.1007/s00401-019-02026-8. [Epub ahead of print]

PMID:
31131421
2.

Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.

Staffaroni AM, Bajorek L, Casaletto KB, Cobigo Y, Goh SM, Wolf A, Heuer HW, Elahi FM, Ljubenkov PA, Dever R, Kornak J, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber D, Caso C, Coppola G, Dheel C, Dickerson BC, Dickinson S, Dominguez S, Domoto-Reilly K, Faber K, Ferrall J, Fields JA, Fishman A, Fong J, Foroud T, Forsberg LK, Gavrilova R, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Hsiung GY, Huey ED, Irwin DJ, Jones DT, Jones L, Kantarci K, Karydas A, Kaufer DI, Kerwin DR, Knopman DS, Kraft R, Kremers WK, Kukull WA, Litvan I, Lucente D, Lungu C, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis SM, McKinley E, Mendez MF, Miller BL, Multani N, Onyike C, Padmanabhan J, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Rascovsky K, Roberson ED, Rogalski E, Sengdy P, Shaw LM, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wang P, Wong B, Wszolek Z, Boxer AL, Boeve BF, Kramer JH, Rosen HJ; ARTFL/LEFFTDS consortium.

Alzheimers Dement. 2019 May 11. pii: S1552-5260(19)30044-5. doi: 10.1016/j.jalz.2019.01.012. [Epub ahead of print]

3.

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2019 Mar 18. doi: 10.1002/mds.27666. [Epub ahead of print]

PMID:
30884545
4.

Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.

Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, Domoto-Reilly K, Duda J, Gomperts S, Graff-Radford N, Holden S, Honig L, Huddleston D, Lippa C, Litvan I, Manning C, Marder K, Moussa C, Onyike C, Pagan F, Pantelyat A, Pelak V, Poston K, Quinn J, Richard I, Rosenthal LS, Sabbagh M, Scharre D, Sha S, Shill H, Torres-Yaghi Y, Christie T, Graham T, Richards I, Koehler M, Boeve B.

Alzheimers Res Ther. 2019 Mar 13;11(1):23. doi: 10.1186/s13195-019-0476-1.

5.

Assessment of APOE in atypical parkinsonism syndromes.

Sabir MS, Blauwendraat C, Ahmed S, Serrano GE, Beach TG, Perkins M, Rice AC, Masliah E, Morris CM, Pihlstrom L, Pantelyat A, Resnick SM, Cookson MR, Hernandez DG, Albert M, Dawson TM, Rosenthal LS, Houlden H, Pletnikova O, Troncoso J, Scholz SW.

Neurobiol Dis. 2019 Jul;127:142-146. doi: 10.1016/j.nbd.2019.02.016. Epub 2019 Feb 21.

PMID:
30798004
6.

Genetic analysis of neurodegenerative diseases in a pathology cohort.

Blauwendraat C, Pletnikova O, Geiger JT, Murphy NA, Abramzon Y, Rudow G, Mamais A, Sabir MS, Crain B, Ahmed S, Rosenthal LS, Bakker CC, Faghri F, Chia R, Ding J, Dawson TM, Pantelyat A, Albert MS, Nalls MA, Resnick SM, Ferrucci L, Cookson MR, Hillis AE, Troncoso JC, Scholz SW.

Neurobiol Aging. 2019 Apr;76:214.e1-214.e9. doi: 10.1016/j.neurobiolaging.2018.11.007. Epub 2018 Nov 17.

PMID:
30528841
7.

Functional Movement Disorders and Placebo: A Brief Review of the Placebo Effect in Movement Disorders and Ethical Considerations for Placebo Therapy.

Kaas BM, Humbyrd CJ, Pantelyat A.

Mov Disord Clin Pract. 2018 Oct 9;5(5):471-478. doi: 10.1002/mdc3.12641. eCollection 2018 Sep-Oct. Review.

PMID:
30515436
8.

Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease.

Kam TI, Mao X, Park H, Chou SC, Karuppagounder SS, Umanah GE, Yun SP, Brahmachari S, Panicker N, Chen R, Andrabi SA, Qi C, Poirier GG, Pletnikova O, Troncoso JC, Bekris LM, Leverenz JB, Pantelyat A, Ko HS, Rosenthal LS, Dawson TM, Dawson VL.

Science. 2018 Nov 2;362(6414). pii: eaat8407. doi: 10.1126/science.aat8407.

9.

Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease.

Hinkle JT, Perepezko K, Mills KA, Mari Z, Butala A, Dawson TM, Pantelyat A, Rosenthal LS, Pontone GM.

Parkinsonism Relat Disord. 2018 Oct;55:8-14. doi: 10.1016/j.parkreldis.2018.08.010. Epub 2018 Aug 22.

PMID:
30146185
10.

Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers.

Hinkle JT, Perepezko K, Bakker CC, Broen MPG, Chin K, Dawson TM, Johnson V, Mari Z, Marvel CL, Mills KA, Pantelyat A, Pletnikova O, Rosenthal LS, Shepard MD, Stevens DA, Troncoso JC, Wang J, Pontone GM.

Mov Disord Clin Pract. 2018 Jan-Feb;5(1):31-38. doi: 10.1002/mdc3.12550. Epub 2017 Sep 15.

11.

Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.

Hinkle JT, Perepezko K, Rosenthal LS, Mills KA, Pantelyat A, Mari Z, Butala A, Moukheiber E, Dawson TM, Pontone GM.

Parkinsonism Relat Disord. 2018 Aug;53:108-109. doi: 10.1016/j.parkreldis.2018.04.027. Epub 2018 May 2. No abstract available.

PMID:
29753604
12.

Telemedicine Use for Movement Disorders: A Global Survey.

Hassan A, Dorsey ER, Goetz CG, Bloem BR, Guttman M, Tanner CM, Mari Z, Pantelyat A, Galifianakis NB, Bajwa JA, Gatto EM, Cubo E.

Telemed J E Health. 2018 Dec;24(12):979-992. doi: 10.1089/tmj.2017.0295. Epub 2018 Mar 22.

PMID:
29565764
13.

Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.

Hinkle JT, Perepezko K, Rosenthal LS, Mills KA, Pantelyat A, Mari Z, Tochen L, Bang JY, Gudavalli M, Yoritomo N, Butala A, Bakker CC, Johnson V, Moukheiber E, Dawson TM, Pontone GM.

Parkinsonism Relat Disord. 2018 Feb;47:50-56. doi: 10.1016/j.parkreldis.2017.11.338. Epub 2017 Nov 21.

14.

Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis.

Hinkle JT, Perepezko K, Bakker CC, Dawson TM, Johnson V, Mari Z, Marvel CL, Mills KA, Pantelyat A, Pletnikova O, Rosenthal LS, Shepard MD, Stevens DA, Troncoso JC, Wang J, Pontone GM.

Int J Geriatr Psychiatry. 2018 Jan;33(1):e131-e139. doi: 10.1002/gps.4736. Epub 2017 May 16.

15.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13. Review.

16.

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):955-971. doi: 10.1002/mds.27038. Epub 2017 May 13. Review.

17.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.

18.

Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes.

Mills KA, Mari Z, Pontone GM, Pantelyat A, Zhang A, Yoritomo N, Powers E, Brandt J, Dawson TM, Rosenthal LS.

Parkinsonism Relat Disord. 2016 Dec;33:107-114. doi: 10.1016/j.parkreldis.2016.09.025. Epub 2016 Sep 27.

19.

Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients.

Mills KA, Mari Z, Bakker C, Johnson V, Pontone GM, Pantelyat A, Troncoso JC, Pletnikova O, Dawson TM, Rosenthal LS.

Parkinsonism Relat Disord. 2016 Dec;33:102-106. doi: 10.1016/j.parkreldis.2016.09.024. Epub 2016 Sep 25.

20.

Changes in Verbal Fluency in Parkinson's Disease.

Rosenthal LS, Salnikova YA, Pontone GM, Pantelyat A, Mills KA, Dorsey ER, Wang J, Wu SS, Mari Z.

Mov Disord Clin Pract. 2016 Oct 1;4(1):84-89. doi: 10.1002/mdc3.12421. eCollection 2017 Jan-Feb.

21.

DRUM-PD: The use of a drum circle to improve the symptoms and signs of Parkinson's disease (PD).

Pantelyat A, Syres C, Reichwein S, Willis A.

Mov Disord Clin Pract. 2016 May-Jun;3(3):243-249. Epub 2015 Dec 21.

22.

Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies.

Geiger JT, Ding J, Crain B, Pletnikova O, Letson C, Dawson TM, Rosenthal LS, Pantelyat A, Gibbs JR, Albert MS, Hernandez DG, Hillis AE, Stone DJ, Singleton AB; North American Brain Expression Consortium, Hardy JA, Troncoso JC, Scholz SW.

Neurobiol Dis. 2016 Oct;94:55-62. doi: 10.1016/j.nbd.2016.06.004. Epub 2016 Jun 14.

23.

C9orf72 Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies.

Geiger JT, Arthur KC, Dawson TM, Rosenthal LS, Pantelyat A, Albert M, Hillis AE, Crain B, Pletnikova O, Troncoso JC, Scholz SW.

Neurodegener Dis. 2016;16(5-6):370-2. doi: 10.1159/000445872. Epub 2016 May 31.

24.

Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta-Analysis.

Brennan L, Pantelyat A, Duda JE, Morley JF, Weintraub D, Wilkinson JR, Moberg PJ.

Mov Disord Clin Pract. 2015 Dec 7;3(2):161-167. doi: 10.1002/mdc3.12264. eCollection 2016 Mar-Apr.

25.

Movement and Other Neurodegenerative Syndromes in Patients with Systemic Rheumatic Diseases: A Case Series of 8 Patients and Review of the Literature.

Menezes R, Pantelyat A, Izbudak I, Birnbaum J.

Medicine (Baltimore). 2015 Aug;94(31):e0971. doi: 10.1097/MD.0000000000000971. Review.

26.

Central neurogenic hyperventilation: A sign of CNS lymphoma.

Pantelyat A, Galetta SL, Pruitt A.

Neurol Clin Pract. 2014 Dec;4(6):474-477. doi: 10.1212/CPJ.0000000000000087. No abstract available.

27.

Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction.

Ross CA, Pantelyat A, Kogan J, Brandt J.

Mov Disord. 2014 Sep 15;29(11):1351-8. doi: 10.1002/mds.26012. Review.

28.

Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism.

Morley JF, Pawlowski SM, Kesari A, Maina I, Pantelyat A, Duda JE.

Parkinsonism Relat Disord. 2014 Jul;20(7):738-42. doi: 10.1016/j.parkreldis.2014.03.024. Epub 2014 Apr 1.

PMID:
24742370
29.

Acalculia in autopsy-proven corticobasal degeneration.

Pantelyat A, Dreyfuss M, Moore P, Gross R, Schuck T, Irwin D, Trojanowski J, Grossman M.

Neurology. 2011 Feb 15;76(7 Suppl 2):S61-3. doi: 10.1212/WNL.0b013e31820c34ca. No abstract available.

30.

Teaching NeuroImages: occlusion of all 4 major extracranial vessels.

Mullen MT, Pantelyat A, Pukenas BA, Messé SR.

Neurology. 2010 Sep 21;75(12):e51. doi: 10.1212/WNL.0b013e3181f39aca. No abstract available.

31.

Macular pigment and lutein supplementation in ABCA4-associated retinal degenerations.

Aleman TS, Cideciyan AV, Windsor EA, Schwartz SB, Swider M, Chico JD, Sumaroka A, Pantelyat AY, Duncan KG, Gardner LM, Emmons JM, Steinberg JD, Stone EM, Jacobson SG.

Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1319-29.

Supplemental Content

Loading ...
Support Center